1039809-89-6 Usage
Uses
Used in Organic Synthesis:
2-(4-methoxybenzyloxy)-5-bromobenzoic acid is used as a key intermediate in organic synthesis for the creation of various organic compounds. Its presence of bromine and methoxy groups allows for further functionalization and modification, making it a valuable precursor in the synthesis of compounds with diverse chemical and biological activities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(4-methoxybenzyloxy)-5-bromobenzoic acid is utilized as a building block for the synthesis of new drugs and pharmaceuticals. Its unique molecular structure and properties contribute to the development of innovative therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Drug Development:
2-(4-methoxybenzyloxy)-5-bromobenzoic acid is employed as a versatile precursor in drug development, where its chemical properties can be harnessed to create novel pharmaceuticals. The presence of bromine and methoxy groups provides opportunities for structural modifications that can enhance the compound's pharmacological profile, potentially leading to the discovery of new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1039809-89-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,9,8,0 and 9 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1039809-89:
(9*1)+(8*0)+(7*3)+(6*9)+(5*8)+(4*0)+(3*9)+(2*8)+(1*9)=176
176 % 10 = 6
So 1039809-89-6 is a valid CAS Registry Number.
1039809-89-6Relevant academic research and scientific papers
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Dai, Xuedong,Long, Kai,Peng, Cheng,Andreotti, Daniele,Bamborough, Paul,Eatherton, Andrew J.,Edge, Colin,Jandu, Karamjit S.,Nichols, Paula L.,Philps, Oliver J.,Stasi, Luigi Piero,Wan, Zehong,Xiang, Jia-Ning,Dong, Kelly,Dossang, Pamela,Ho, Ming-Hsun,Li, Yi,Mensah, Lucy,Guan, Xiaoming,Reith, Alastair D.,Ren, Feng
supporting information, p. 4034 - 4038 (2017/08/23)
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.
NOVEL COMPOUNDS
-
Page/Page column 53; 54, (2011/04/25)
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
